Overview

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of peri- and postmenopausal women with major depressive disorder

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Desvenlafaxine Succinate